Komori
Other Disclosures4896K Pharma,Inc.Pharmaceuticals

Notice of Update to the Financial Results Report for the First Quarter of the Fiscal Year Ending December 2026

The Japanese- and English-language versions of ケイファーマ’s first-quarter earnings report for the fiscal year ending December 2026, prepared by a third-party research company, were updated and made available on 12 June 2026.

Worth reading
43Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

First-quarter earnings report for the fiscal year ending December 2026
Applicable field (uses covered by this announcement)

Information provision for investors and investment decisions

Launch date12 June 2026 (actual date on which publication began)
Relationship between the counterparty and the company
K Pharma,Inc.4896
Relationship with the Company

A business relationship in which 株式会社シェアードリサーチ prepares and updates the Company’s earnings reports. Capital and personnel relationships are not disclosed.

CounterpartyShared Research Inc.

A research company that prepares reports based on research and analysis from a third-party perspective. Other information about the company is not disclosed.

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

Research and analysis from a third-party perspective by Shared Research Inc.

Announced details
ItemDetails
Names of Products / Services CoveredFirst-quarter earnings report for the fiscal year ending December 2026
CounterpartyShared Research Inc.
Counterparty overviewA research company that prepares reports based on research and analysis from a third-party perspective. Other information about the company is not disclosed.
Relationship with the CompanyA business relationship in which 株式会社シェアードリサーチ prepares and updates the Company’s earnings reports. Capital and personnel relationships are not disclosed.
Launch date12 June 2026 (actual date on which publication began)
Applicable areaInformation provision for investors and investment decisions
SourceResearch and analysis from a third-party perspective by Shared Research Inc.
Items this document does not state (11)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To help investors deepen their understanding of our business overview, business strategy and future growth strategy, and use the information as a reference when making investment decisions.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Update to the Financial Results Report for the First Quarter of the Fiscal Year Ending December 2026 | K Pharma,Inc. (4896) timely disclosure | Komori